Kedrion Biopharma participates in ISTH 2025, taking place in Washington, D.C., from June 21 to 26. As a company committed to rare and ultra-rare diseases, Kedrion will bring to the global stage a strong scientific and educational presence, fostering knowledge exchange and meaningful dialogue within the bleeding disorders community.
Kedrion will host two scientific industry symposiums focused on the clinical understanding and management of two ultra rare diseases.
On June 23rd “Understanding Hereditary Factor X Deficiency to optimize clinical management” Prof. Flora Peyvandi (moderator) will open the session with a welcome and introduction, followed by two expert-led presentations. Dr. Meera Chitlur will discuss the management of HFXD in pediatric patients, focusing on when the adoption of prophylaxis is most appropriate. Dr. Miguel Escobar will then provide a closer look at surgical considerations in HFXD patients. Through this focused program, attendees will gain practical insights into the evolving approaches for optimizing care in this rare bleeding disorder.
Then on June 24th symposium “Plasminogen Deficiency: a rare multi-system disorder” will offer a comprehensive look into this under-recognized condition. Moderated by Karen Thibaudeau, the session will begin with an introduction to PLGD-1 and the featured speakers. Dr. Amy Shapiro will follow with a compelling presentation on the disease, its diagnosis, and current treatment options. Dr. Alfonso Iorio will then explore the role of WAPPS Hemo and pharmacokinetic (PK) profiling in optimizing treatment strategies. This symposium aims to raise awareness, share clinical insights, and foster improved management of patients affected by this rare multi-system disorder.
In addition, Kedrion supports a poster presentation “Challenging Established Paradigms: Lack of Correlation Between Factor X Levels and ISTH-BAT Scores in Factor x Deficiency” and is present with two product booths offering opportunities for scientific exchange and showcasing the company’s ongoing innovation in support of patients worldwide. An international delegation of leading Key Opinion Leaders (KOLs) will also join Kedrion’s activities, contributing to scientific dialogue and reinforcing the collaborative spirit of the congress.
Through our participation at ISTH 2025, we reaffirm a long-standing dedication to supporting clinicians, advancing research, and, above all, improving the lives of people affected by rare and ultra-rare bleeding disorders.
SAVE THE DATE
Presentation theaters:
Understanding Hereditary Factor X Deficiency to Optimize Clinical Management
Monday, June 23 | 7:00–7:45 AM | Room 203 A&B
Moderator: Prof. Flora Peyvandi (Italy)
Speakers: Dr. Meera Chitlur (USA), Dr. Miguel Escobar (USA)
Plasminogen Deficiency: a Rare Multi-System Disorder
Tuesday, June 24 | 7:00–7:45 AM | Room 203 A&B
Moderator: Karen Thibaudeau
Speakers: Dr. Amy Shapiro (USA), Dr. Alfonso Iorio (Canada)
Poster presentation:
“Challenging Established Paradigms: Lack of Correlation Between Factor X Levels and ISTH-BAT Scores in Factor x Deficiency”
Authors: S. Halimeh (Duisburg), S. Alesci (Bad Homburg), A Kleyn (Kedrion)